COMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
|
|
- Barbara Owen
- 5 years ago
- Views:
Transcription
1 Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL PROPERTIES PHARMACODYNAMICS Rotazar is an antihypertensive drug, a selective antagonist of angiotensin II receptors (АТ 1 type). It blocks all physiologically significant effects of angiotensin II fulfilled via AT 1-receptors regardless of the source or the pathway of angiotensin II synthesis. Specific antagonistic action against AT 1- receptors results in an increase of plasma renin and angiotensin II levels and in a decrease in plasma aldosterone concentration. If the drug is administered in the recommended doses, no significant alteration of serum potassium ion concentration is observed. Irbesartan does not inhibit kininase II (ACE), via which angiotensin II is formed and bradykinin is degraded to inactive metabolites. Irbesartan does not require metabolic activation for development of its action. Irbesartan decreases arterial pressure (AP) with minimum alteration of heart rate (HR). AP decreases in a dose-dependent manner when the drug is administered in doses up to 300 mg once daily, but further increase in irbesartan dosage results in a negligible potentiation of the hypotensive effect. The peak decrease in AP is achieved within 3-6 hours after oral administration of the drug. The hypotensive effect maintains for not less than 24 hours. AP decrease 24 hours after administration of the recommended doses is 60-70% compared to the peak decrease in diastolic and systolic AP in response to the drug. Once daily administration of the drug in doses of mg results in the mean degree of AP reduction (systolic/diastolic) at the end of interdose interval (i.e. 24 hours after administration of the drug) in a supine or a sitting position by 8-13/5-8 mm Hg (respectively) compared to placebo. Once daily administration of the drug in a dose of 150 mg exhibits the same hypotensive effect (AP reduction before administration of the next dose of the drug and the mean decrease in AP over 24 hours) as administration of the same dose divided in 2 doses. The hypotensive action of Rotazar develops within 1-2 weeks; the maximum therapeutic effect is achieved within 4-6 weeks after the beginning of treatment. The antihypertensive effect is
2 maintained in prolonged therapy as well. After termination of treatment AP gradually returns to the initial value; no withdrawal syndrome has been observed. Irbesartan does not affect serum concentrations of uric acid or excretion of uric acid in urine. Efficiency of Rotazar does not depend on age or gender. PHARMACOKINETICS Absorption After oral administration the drug is well absorbed from the gastrointestinal tract (GIT). The peak plasma irbesartan concentration is achieved within hours after oral administration. Absolute bioavailability is 60-80%. Concomitant food intake does not significantly influence the bioavailability of the drug. Pharmacokinetics of irbesartan is linear and dose-proportional in the dose interval from 10 to 600 mg; in doses over 600 mg (2 times higher than the maximum recommended dose) irbesartan kinetics becomes non-linear (the absorption decreases). Distribution Plasma protein binding is about 96%. Binding with cellular constituent of blood is insignificant. Distribution volume is l. Irbesartan accumulation in plasma in repeated once daily administration is limited (less than 20%). Metabolism Irbesartan is biotransformed in liver by way of oxidation and conjugation with glucuronic acid. Irbesartan is oxidized mainly by isoenzyme CYP2С9; involvement of isoenzyme CYP3A4 in irbesartan metabolism is negligible. The main metabolite present in systemic circulation is irbesartan glucuronide (about 6%). Excretion Total body clearance and renal clearance are ml/min and ml/min, respectively. Terminal elimination half-life (T 1/2) is hours. Irbesartan and its metabolites are excreted in bile and urine. After oral administration of 14С-irbesartan about 20% of radioactivity is recovered in urine, and the rest - in faeces. Less than 2% of the administered dose is eliminated in urine as unchanged irbesartan. Pharmacokinetics in particular medical cases Women demonstrate a little higher plasma concentrations of irbesartan (compared to men). Still, no differences in T 1/2 values and accumulation of irbesartan have been observed. No dose adjustment is required for women. The values of AUC and the peak irbesartan concentration were somewhat higher in elderly patients ( 65 years old) than in younger ones, but no reliable differences in terminal T 1/2 have been observed.
3 Pharmacokinetic parameters of irbesartan in patients with impaired renal function or in patients undergoing hemodialysis do not significantly change. Irbesartan is not eliminated via hemodialysis. Pharmacokinetic parameters of irbesartan in patients with mild or moderate liver cirrhosis do not significantly change. No pharmacokinetic studies have been performed in patients with severe hepatic failure. THERAPEUTİC İNDİCATİONS - essential arterial hypertension; - nephropathy in patients with arterial hypertension and type 2 diabetes mellitus (as part of combined hypotensive therapy). CONTRAINDICATIONS - hypersensitivity to the components of the drug; - hereditary galactose intolerance, lactase deficiency or malabsorption of glucose and galactose; - pregnancy; - lactation; - children and adolescents under 18 years old (efficiency and safety have not been determined). Exercise caution administering the drug in aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, dehydration, hyponatremia, diarrhea, vomiting, diet with limited consumption of salt, diuretic therapy, bilateral stenosis of renal arteries, unilateral stenosis of the artery of the single present kidney, chronic heart failure of the III-IV functional class according to NYHA classification, IHD and/or atherosclerotic damage of cerebral vessels, hyperkalemia, renal failure, hemodialysis, recent transplantation of a kidney (absence of clinical experience of administration), severe renal failure (absence of clinical experience of administration). ADVERSE EFFECTS Arterial hypertension Central nervous system disorders: common - dizziness. Cardiovascular system disorders: uncommon - tachycardia, skin hyperemia. Respiratory system disorders: uncommon - cough. Gastrointestinal tract disorders: common - nausea, vomiting; uncommon - diarrhea, dyspepsia, heartburn. Reproductive system disorders: uncommon - sexual dysfunction.
4 General body disorders: common - fatigue; uncommon - chest pain. Abnormal laboratory test results: common - proved increase in CPK level, not accompanied with clinical manifestations on the part of the musculoskeletal system. Arterial hypertension and type 2 diabetes mellitus with kidney damage Apart from the side effects described for patients with arterial hypertension, 0.5% of patients with arterial hypertension, type 2 diabetes mellitus with microalbuminuria and without renal failure reported orthostatic dizziness and orthostatic hypotension during treatment with irbesartan (compared to the frequency of such reactions during treatment with placebo). In > 2% (compared to the frequency during treatment with placebo) of patients with arterial hypertension, type 2 diabetes mellitus with pronounced proteinuria and chronic renal failure the following adverse reactions were observed. Nervous system disorders: common - orthostatic dizziness. Cardiovascular system disorders: common - orthostatic hypotension. Musculoskeletal disorders: common - muscle and bone pain. Abnormal laboratory test results: hyperkalemia during treatment of diabetic patients with irbesartan was observed more frequently than during treatment with placebo. Among diabetic patients with increased AP and microalbuminuria with normal renal function hyperkalemia ( 5.5% mmol/l) was observed in 29.4% of patients treated with irbesartan in a dose of 300 mg (very common) and in 22% of patients in the placebo group. Among diabetic patients with increased AP, chronic renal failure and pronounced proteinuria hyperkalemia ( 5.5% mmol/l) was observed in 46.3% of patients treated with irbesartan (very common) and in 26.3% of patients in the placebo group. 1.7% of patients with increased AP and diabetic nephropathy, treated with irbesartan, demonstrated clinically insignificant decrease in hemoglobin concentration (common). DOSAGE AND ADMİNİSTRATİON The drug is administered orally. The tablet is swallowed whole, followed with water. The initial and maintenance doses are 150 mg once daily regardless the timing of meals. Administration of the drug in such doses ensures better 24-hour control of AP, than in doses of 75 mg daily. But in some cases, especially in patients undergoing hemodialysis or in patients older than 75 years, the initial dose should be 75 mg. In case of insufficient therapeutic effect of Rotazar in a dose of 150 mg once daily the dose may be increased to 300 mg or another antihypertensive drug may be prescribed. Particularly, it was shown that administration of the diuretic hydrochlorothiazide potentiated the effect of Rotazar. Treatment of patients with arterial hypertension and type 2 diabetes mellitus should be started with a dose of 150 mg once daily and gradually increased to 300 mg which is the preferable maintenance dose for treatment of nephropathy.
5 In patients with water and electrolytic imbalance the circulating blood volume (CBV) should be restored and/or hyponatremia should be eliminated before treatment with the drug. No dose regimen adjustment is required in patients with renal dysfunction. The initial dose for patients undergoing hemodialysis should be 75 mg daily. No dose regimen adjustment is required in patients with mild or moderate hepatic dysfunction. Clinical experience of administration of the drug in patients with severe hepatic dysfunction is absent. Although the recommended initial dose for patients aged over 75 years is 75 mg, no dose adjustment is usually required. PACKAGING Film coated tablets. 14 tablets in a blister. 2 blisters together with a leaflet in a carton box.
MICARDIS Composition Pharmacological properties Pharmacokinetics
MICARDIS Boehringer (Tablet) Composition 1 tablet contains 40 or 80 mg [1,1 -biphenyl]-2-carboxylic acid, 4 -[(1,4 dime-thyl- 2 -propyl[2,6-bi-1h-benzimidazole]-1 -yl)methyl] (= telmisartan) Excipients:
More informationAmlodipine plus Lisinopril Tablets AMLOPRES-L
Amlodipine plus Lisinopril Tablets AMLOPRES-L COMPOSITION AMLOPRES-L Each uncoated tablet contains: Amlodipine besylate equivalent to Amlodipine 5 mg and Lisinopril USP equivalent to Lisinopril (anhydrous)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Irbesartan BMS 75 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 75 mg of irbesartan. Excipient:
More informationAPROVEL 150 mg/300 mg Sanofi-Aventis
APROVEL 150 mg/300 mg Sanofi-Aventis Composition Aprovel 150 mg tablets: each tablet contains 150 mg irbesartan. Aprovel 300 mg tablets: each tablet contains 300 mg irbesartan. Presentation Tablet: White
More informationazilsartan medoxomil
azilsartan medoxomil edarbi 40mg Tablet 80mg Tablet ANTIHYPERTENSIVE Angiotensin II Receptor Antagonist FORMULATION: Each tablet contains 40mg Azilsartan medoxomil (as potassium) Each tablet contains 80mg
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationModule 1.3 Product Information Version: Module Summary of Product Characteristics Replaces :
Irbesartan Apotex Europe B.V. 75 mg, 150 mg, 300 mg film- coated tablets Module 1.3 Product Information Version: 2010-07-01 Module 1.3.1 Summary of Product Characteristics Replaces : 2010-01-20 SUMMARY
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Aprovel 75 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 75 mg of irbesartan. Excipient with
More informationPRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T
PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in
More informationPHARMACEUTICAL INFORMATION AZILSARTAN
AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each film - coated tablet contains 150 mg Irbesartan.
1.3.1.1 Summary of product characteristics 1. NAME OF THE MEDICINAL PRODUCT Irbesartan Accord 150 mg Film-coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film - coated tablet contains 150
More informationPATIENT INFORMATION LEAFLET DYNARB RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNARB 75 mg tablets DYNARB 150 mg tablets DYNARB 300 mg tablets Read all of this leaflet carefully before you start taking DYNARB.
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Irbesartan 75 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Irbesartan 75 mg film-coated tablet contains 75 mg
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Irbesan 150mg Film-coated Tablets Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film- coated tablet contains 150 mg irbesartan. Excipient
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationLOZAR. Composition Each tablet contains Losartan potassium 50 mg.
LOZAR Composition Each tablet contains Losartan potassium 50 mg. Tablets Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is
More informationINSTRUCTION for medical use KLOSART
APPROVED The Order of Ministry of Health of Ukraine 13.07.2018 1309 Registration certificate UA/8765/01/01 UA/8765/01/02 UA/8765/01/03 INSTRUCTION for medical use KLOSART Composition: active substance:
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Irbesartan 75mg Film-coated Tablets Irbesartan 150mg Film-coated Tablets Irbesartan 300mg Film-coated Tablets irbesartan Read all of this leaflet carefully before
More informationMTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride
MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Page 1 of 7
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prilocard 5mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationPRUCAPLA Tablets (Prucalopride)
Published on: 2 May 2018 PRUCAPLA Tablets (Prucalopride) Composition PRUCAPLA 1 mg Each film coated tablet contains: Prucalopride succinate equivalent to Prucalopride 1 mg Excipients. q. s. Color: Titanium
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationThe P&T Committee Lisinopril (Qbrelis )
Situation Background Assessment The P&T Committee Lisinopril (Qbrelis ) Qbrelis, 1 mg/ml lisinopril oral solution, has recently become an FDA- approved formulation. Current practice at UK Chandler Medical
More informationPhysiotens 0.2 mg Abbott
10-14 Physiotens 0.2 mg Abbott Film-coated tablets 0.2 mg moxonidine Physiotens 0.2 mg tablets are round, convex, light pink, film-coated tablets with the stamp «0.2» on one face. Each tablet contains
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Edarbi 20 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg of azilsartan medoxomil (as potassium).
More informationComposition: Each Tablet contains. Pharmacokinetic properties:
Composition: Each Tablet contains Torsemide 5/10/20/40/100mg Pharmacokinetic properties: Torsemide is well absorbed from the gastrointestinal tract. Peak serum concentrations are achieved within 1 hour
More informationSpironolactone has not been demonstrated to elevate serum uric acid, to precipitate gout or to alter carbohydrate metabolism.
SPIRONE Composition Each tablet contains Spironolactone 100 mg. Tablets Action Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors
More informationData Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.
BICALOX Data Sheet Bicalutamide 50 mg tablets Presentation BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. Uses Actions
More informationCEDIAMATE Metformin Tablets USP 500 mg
CEDIAMATE Metformin Tablets USP 500 mg COMPOSITION: Cediamate Each un-coated tablet contains: Metformin Hydrochloride USP Excipients 500 mg Q.S PHARMACOLOGY: Pharmacotherapeutic group: Blood Glucose lowering
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationEplerenon Medical Valley + Eplerenon Stada
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Heart failure is a complex syndrome, clinically characterized by signs and symptoms secondary to abnormal cardiac function. It
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Amias 2 mg Tablets. Amias 4 mg Tablets. Amias 8 mg Tablets. Amias 16 mg Tablets. Amias 32 mg Tablets. 2. QUALITATIVE AND QUANTITATIVE
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationCRESAR Tablets (Telmisartan)
Published on: 10 Jul 2014 CRESAR Tablets (Telmisartan) Composition Black Box Warning: Fetal Toxicity When pregnancy is detected, discontinue telmisartan as soon as possible. Drugs that act directly on
More informationEach tablet contains:
Composition: Each tablet contains: Tolvaptan 15/30mg Pharmacokinetic properties: In healthy subjects the pharmacokinetics of tolvaptan after single doses of up to 480 mg and multiple doses up to 300 mg
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPRODUCT INFORMATION TEVETEN. Eprosartan mesylate has a molecular weight (MW) of and may be represented structurally as:
NAME OF THE MEDICINE Non-proprietary Name Eprosartan mesylate Chemical Structure PRODUCT INFORMATION TEVETEN Eprosartan mesylate has a molecular weight (MW) of 520.6 and may be represented structurally
More informationCOZAAR Merck Sharp & Dhome
COZAAR Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT Cozaar 50 and Cozaar 100 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Cozaar contains 50 mg or 100 mg of losartan potassium. For
More informationAPO- IRBESARTAN TABLETS. 2-butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro [4,4] non-1- en-4-one.
APO- IRBESARTAN TABLETS NAME OF THE MEDICINE Irbesartan Chemical Name: 2-butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro [4,4] non-1- en-4-one. Structural Formula: Molecular Formula:
More informationPRESCRIBING INFORMATION (PI)
PRESCRIBING INFORMATION (PI) BYDUREON (exenatide) 2MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR INJECTION, PREFILLED
More informationGlucophage XR is contra-indicated during breast-feeding.
Name GLUCOPHAGE XR 1000 mg Prolonged release tablets Active ingredient Metformin hydrochloride Composition Each Glucophage XR 1000 mg prolonged release tablet contains as active ingredient 1000 mg metformin
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1Overview of disease epidemiology 1 Losartan is indicated for: Treatment of essential hypertension in adults and in children and adolescent 6 18 years of age. Treatment
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More informationEmergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Candesartan cilexetil 16 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Kairasec 16 mg tablets: Each tablet contains 16 mg of candesartan
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationHYZAAR Merck Sharp & Dhome
HYZAAR Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT HYZAAR * 50/12.5 2. QUALITATIVE AND QUANTITATIVE COMPOSITION HYZAAR contains 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide.
More informationVI.2 Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Product therapeutic indications: Myocardial infarction is the medical term for an event commonly known as a heart attack. It happens
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cozatan 50 mg film-coated tablets Cozatan 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Cozatan 50 mg tablet
More informationTelmisartan Pritor Tablets
Telmisartan Pritor Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Telmisartan (Pritor TM ) 40 mg Tablet: Each tablet contains 40 mg Telmisartan. Telmisartan (Pritor TM ) 80 mg Tablet: Each tablet contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More informationIrbenida 150 mg film-coated tablets; 300 mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida 150 mg film-coated tablets; 300 mg film-coated tablets IRBESARTAN This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationLOSARTAN + HYDROCHLOROTHIAZIDE HYZAAR /HYZAAR DS
PRODUCT CIRCULAR WPC-HYZ-T-092007 THERAPEUTIC CLASS LOSARTAN + HYDROCHLOROTHIAZIDE HYZAAR /HYZAAR DS Film-Coated Tablet Antihypertensive LOSARTAN + HYDROCHLOROTHIAZIDE (HYZAAR) is the first combination
More informationDorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )
INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the
More information1. NAME OF THE MEDICINAL PRODUCT. Cinfaval cinfa 40 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Cinfaval cinfa 40 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Cinfaval 40 mg film-coated tablets Each tablet contains 40 mg of valsartan. Excipients:
More informationNARAMIG QUALITATIVE AND QUANTITATIVE COMPOSITION
NARAMIG Naratriptan QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing 2.5 mg of naratriptan as naratriptan hydrochloride. PHARMACEUTICAL FORM Film coated tablets. CLINICAL PARTICULARS Indications
More informationProduct Information Avapro (irbesartan)
Product Information Avapro (irbesartan) NAME OF THE MEDICINE Australian Approved Name Irbesartan. Irbesartan is 2-butyl-3-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro [4,4] non- 1-en-4-one.
More informationCONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients
Galvus PRESENTATION: Each tablet contains 50 mg of Vildagliptin INDICATIONS: For the treatment of type 2 diabetes mellitus in adults: i) As monotherapy in patients inadequately controlled by diet and exercise
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Losartan Mylan 12.5 mg film-coated tablets Losartan Mylan 25 mg film-coated tablets Losartan Mylan 50 mg film-coated tablets Losartan
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationIrbenida H 150mg/12,5mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Irbenida H 150mg/12,5mg film-coated tablets IRBESARTAN/HYDROCHLOROTHIAZIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Metformin HCl Bluefish 500 mg, film-coated tablets Metformin HCl Bluefish 850 mg, film-coated tablets Metformin HCl Bluefish 1000 mg,
More informationAUSTRALIAN PRODUCT INFORMATION APO- IRBESARTAN (IRBESARTAN) TABLETS
AUSTRALIAN PRODUCT INFORMATION APO- IRBESARTAN (IRBESARTAN) TABLETS 1 NAME OF THE MEDICINE Irbesartan 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 75 mg, 150 mg or 300 mg irbesartan,
More informationART 50 Capsules. Symptomatic treatment of functional symptoms and signs of osteoarthritis.
Doctor leaflet Art50-DL-March2012-01 ART 50 Capsules 1. NAME OF THE MEDICINAL PRODUCT Art 50 mg, capsule. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule of ART 50 contains Diacerein 50 mg. For
More informationPage 1 of DOSAGE FORMS AND STRENGTHS Tablets: 75 mg, 150 mg, 300 mg (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS.
More informationPRODUCT INFORMATION Panadeine EXTRA
PRODUCT INFORMATION Panadeine EXTRA COMPOSITION Each caplet brand of capsule-shaped tablet contains: Paracetamol 500 mg Codeine phosphate 15 mg and Maize Starch Purified Talc Pregelatinised Maize Starch
More informationScientific conclusions
Annex II Scientific conclusions and grounds for amendment of the summary of product characteristics, labelling and package leaflet presented by the European Medicines Agency 18 Scientific conclusions Overall
More informationEach film-coated tablet contains metformin hydrochloride 850 mg corresponding to metformin base 662,9 mg
SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metformin Actavis 850 mg film-coated tablet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains metformin
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationP-RMS: FR/H/PSUR/0056/001
Core Safety Profile Active substance: Piretanide Pharmaceutical form(s)/strength: Tablets, 3mg, 6mg Capsules, 6mg Ampoules, 6mg, 12mg, 60mg P-RMS: FR/H/PSUR/0056/001 Date of FAR: 21.12.2009 4.2 Posology
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 Name of the medicinal product Valsanorm 80 mg film-coated tablets Valsanorm 160 mg film-coated tablets 2 Qualitative and quantitative composition One film-coated tablet
More informationPackage Insert. Cognitin
Package Insert Cognitin Product Summary 1. Name of the medicinal product Cognitin 2. Qualitative and quantitative composition Each film coated tablet contains extract 60 mg 5mg 3. Pharmaceutical form Film
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 20 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg telmisartan Excipients
More informationLevocetirizine dihydrochloride
Levocetirizine dihydrochloride Xyzal Oral Preparations PRODUCT DESCRIPTION Each film-coated tablet of Levocetirizine dihydrochloride (Xyzal ) contains 5 mg of levocetirizine. Each ml of Levocetirizine
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 PRODUCT NAME TROPISETRON-AFT tropisetron hydrochloride (equivalent to 2 mg or 5 mg tropisetron) per ampoule. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 1 mg of tropisetron 1 2 ml ampoule
More informationCHOLESTAGEL 625 mg Genzyme
CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter
More informationALFUSIN Tablets (Alfuzosin hydrochloride)
Published on: 20 Sep 2014 ALFUSIN Tablets (Alfuzosin hydrochloride) Composition Each film-coated extended-release tablet contains: Alfuzosin hydrochloride Ph.Eur... 10 mg Dosage Form Extended-release tablet
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 3 mg/ml oral solution B/1 160 ml (CIP code: 491 474-8) Applicant: NOVARTIS PHARMA SAS valsartan
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Valsartan Sandoz 40 mg film-coated tablets Valsartan Sandoz 80 mg film-coated tablets Valsartan Sandoz 160 mg film-coated tablets Valsartan
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Telmisartan Actavis 20 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg telmisartan For the
More informationPatient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton
Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document
More informationB. PACKAGE LEAFLET. Page 1 of 6
B. PACKAGE LEAFLET Page 1 of 6 PACKAGE LEAFLET Prilocard 1.25 mg, 2.5 mg, 5 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE
More information* Adults. NSAID associated peptic ulceration: - Acute treatment: 150 mg twice daily for 8 to 12 weeks, or 300mg nocte.
Trade Name Aciloc 75 mg & 300 mg Film-coated tablets Generic Name Ranitidine Composition Each Aciloc 300 mg film-coated tablet contains: - Active ingredient: Ranitidine hydrochloride 336 mg equivalent
More informationP-RMS: IE/H/PSUR/0014/002
Core Safety Profile Active substance: Nitroglycerin Pharmaceutical form(s)/strength: Transdermal patch 25mg, 50mg, 75mg (corresponding to 5, 10 and 15mg per 24 hours respectively P-RMS: IE/H/PSUR/0014/002
More informationPackage Insert. Constipeg
Package Insert Constipeg Product Summary 1. Name of the medicinal product Constipeg sachets 2. Qualitative and quantitative composition Each 13.7 g sachet contains PEG polyethylene glycol (macrogol) USNF
More information